Our Pricing

Wegovy Prescribed Online UK: Fast Clinical Assessment

Published on: June 03, 2026

If you're looking to get Wegovy prescribed online UK, Cured Pharmacy offers a streamlined clinical assessment completed in under 3 minutes by UK-registered prescribers. Our transparent pricing starts from £79.00, with genuine UK-licensed semaglutide pens delivered discreetly to your door.

How Wegovy Prescribed Online Works at Cured Pharmacy

Getting Wegovy prescribed online through Cured Pharmacy involves a straightforward three-step process overseen by our UK-registered clinical team. You'll complete a confidential medical questionnaire covering your weight history, current medications, and relevant health conditions. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) leads a team of UK prescribers who review every assessment within hours, not days.

Once your clinical assessment is approved, your Wegovy prescription is dispensed from our GPhC-registered pharmacy (9012511) and dispatched in 100% discreet packaging. All semaglutide pens are sourced directly from UK-licensed wholesalers, ensuring full traceability and compliance with MHRA standards. You'll receive tracking details and can contact our clinical team on (+44) 116 4646009 with any questions throughout your treatment journey.

Clinical Evidence Behind Semaglutide for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural gut hormone to reduce appetite and slow gastric emptying [1]. In the landmark STEP 1 trial, participants using semaglutide 2.4mg weekly achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. This represented the most significant weight loss outcome seen in any pharmacological obesity trial at the time of publication.

The STEP programme included over 4,500 adults across five major trials, demonstrating consistent efficacy across diverse populations [2]. Participants also showed improvements in cardiovascular risk markers, including reductions in waist circumference, blood pressure, and HbA1c levels in those with prediabetes [2]. These findings led to NICE guidance recommending semaglutide as a specialist treatment option for weight management in the UK, subject to specific eligibility criteria [3].

Who Can Be Prescribed Wegovy Online?

UK prescribers assess eligibility based on MHRA-approved criteria: adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea. Your online assessment will screen for contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastrointestinal disease. Pregnant or breastfeeding individuals cannot be prescribed Wegovy, and the medication requires caution in those with a history of pancreatitis.

Wegovy Dosing Schedule and What to Expect

Wegovy follows a structured dose escalation protocol designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes [4]. You'll start with 0.25mg once weekly for four weeks, then increase every four weeks through 0.5mg, 1mg, and 1.7mg, reaching the maintenance dose of 2.4mg by week 17. Each pre-filled pen delivers a single dose, injected subcutaneously into your abdomen, thigh, or upper arm on the same day each week.

Most patients notice appetite reduction within the first two weeks, though significant weight loss typically becomes apparent after reaching higher doses [4]. Clinical trials showed the majority of weight loss occurred between weeks 20 and 60, with continued gradual reduction thereafter [1]. If you experience persistent nausea or vomiting during dose escalation, your prescriber may recommend staying at your current dose for an additional four weeks before increasing. Maintaining the treatment alongside dietary modifications and increased physical activity produces optimal long-term results.

Managing Common Side Effects

Gastrointestinal effects are the most frequently reported side effects with semaglutide, affecting up to 44% of users in clinical trials [1]. Nausea, diarrhoea, constipation, and abdominal discomfort typically peak during dose escalation phases and diminish as your body adapts. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can significantly reduce symptom severity. If side effects become troublesome, contact your prescriber rather than stopping treatment abruptly — dose adjustment or temporary maintenance at a lower dose often resolves issues whilst preserving weight loss progress.

Wegovy Storage and Handling Requirements

Proper storage is essential for maintaining Wegovy's efficacy throughout your treatment. Unopened pens must be refrigerated between 2°C and 8°C until first use — store them in the original carton to protect from light. Once you begin using a pen, it can remain at room temperature (below 30°C) or continue refrigerated for up to 28 days. Never freeze Wegovy pens, and discard any that have been frozen as freezing denatures the semaglutide molecule and renders it ineffective.

If you're travelling, Wegovy can safely remain out of refrigeration for up to 28 days provided it stays below 30°C [5]. Use an insulated medication travel case with ice packs for longer journeys, ensuring the pen doesn't come into direct contact with ice. Always check the solution before injecting — it should be clear and colourless. Discard any pen showing particles, cloudiness, or discolouration. Keep all pens away from direct sunlight and heat sources, and dispose of used pens in a sharps container available free from your local pharmacy.

Wegovy vs Other Weight Loss Treatments Available Online

Several prescription weight loss medications are available through UK online pharmacies, each with distinct mechanisms and clinical profiles. Semaglutide-based treatments like Wegovy activate GLP-1 receptors exclusively, whilst newer dual-agonist medications target both GLP-1 and GIP pathways. Liraglutide, an earlier GLP-1 medication requiring daily injections, produces more modest weight loss averaging 8% in clinical trials compared to semaglutide's 15% [6].

Your choice depends on multiple factors including your weight loss goals, injection frequency preference, side effect tolerance, and budget. Dual-agonist medications have shown superior weight loss outcomes in head-to-head trials but come at higher cost. Daily injectable options may suit those who prefer smaller, more frequent doses to manage side effects. Your UK prescriber will discuss these options during your online consultation, tailoring recommendations to your individual clinical profile and circumstances.

Switching Between Weight Loss Medications

If you're currently using another GLP-1 medication or considering switching to Wegovy, your prescriber will create a safe transition plan. Generally, you'll discontinue your current medication and start Wegovy at the initial 0.25mg dose, following the standard escalation schedule. Some patients switching from daily liraglutide to weekly semaglutide report improved convenience and enhanced weight loss, though individual responses vary. Always complete your switch under prescriber supervision rather than self-adjusting, as overlapping GLP-1 medications increases hypoglycaemia risk in those taking diabetes medications.

Long-Term Weight Maintenance with Wegovy

Clinical evidence demonstrates that semaglutide's weight loss effects are maintained with continued treatment but may reverse upon discontinuation [7]. The STEP 4 trial showed that participants who stopped semaglutide after 20 weeks regained approximately two-thirds of their lost weight over the subsequent 48 weeks, whilst those continuing treatment maintained their reduction [7]. This highlights that Wegovy functions as a long-term weight management medication rather than a short-term solution.

Successful long-term outcomes require integrating Wegovy into broader lifestyle modifications including sustainable dietary changes and regular physical activity. Research indicates that patients who combine semaglutide with structured behavioural support programmes achieve superior maintenance compared to medication alone [8]. Your prescriber will schedule regular follow-up assessments every three to six months to monitor progress, adjust dosing if needed, and provide ongoing support. If you reach your target weight and maintain it for several months, your clinical team may discuss very gradual dose reduction strategies, though most patients require ongoing treatment to prevent regain.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
4. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
5. Medicines and Healthcare products Regulatory Agency. (2023). Semaglutide (Wegovy): storage and handling guidance. GOV.UK. https://www.gov.uk/drug-safety-update/semaglutide-wegovy-storage-handling [accessed 13 August 2026]
6. Pi-Sunyer, X., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
7. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
8. Wadden, T. A., et al. (2021). Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA, 325(14), 1403–1413. https://doi.org/10.1001/jama.2021.1831 [accessed 13 August 2026]
9. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
10. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
11. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine and is subject to prescriber approval based on clinical eligibility criteria. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence, lifestyle modifications, and individual metabolic response.